Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 389-401

  Scali, Juan José ^a   Visentini, S ^a   Salomon J ^a   Sevilla, D ^a   Ju, Y C ^a   Morales, E ^a   Ugarte, L ^a   Tachdjian, A ^a   Pacheco, G ^a   Veiga, S ^a  

^a HOSPITAL DURAND   (Argentina)

Author keywords

Deep control of inflammation; Infliximab; Rheumatoid arthritis

Indexed keywords

AMINOTRANSFERASE; DICLOFENAC; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ACUTE PHASE RESPONSE; ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; OSTEOMYELITIS; PAIN; PHARYNGITIS; POLYMERASE CHAIN REACTION; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SHORT FORM 36; SINUSITIS; TREATMENT DURATION;

EID: 35748975957     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.041     Document Type: Conference Paper

References (21)

1. SCOTT, D.L. & G.H. KINGSLEY. 2006. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355: 704-712.
2. O'SULLIVAN, J.M. & E.S. CATHCART. 1972. The prevalence of rheumatoid arthritis: follow up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann. Intern. Med. 76: 573-577.
3. SOCIEDAD ARGENTINA DE REUMATOLOGÍA (SAR). 2004. Primeras Guías Argentinas de la práctica Clínica en el tratamiento de la Artritis Reumatoidea. Sociedad Argentina de Reumatología 1: 27-30.
4. CHO, Y.E.H. & G.S. PANAYI. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916.
5. BUKHAR, M.I. et al. 2002. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. 46: 906-912.
6. VAN DER HEIJDE, D.M. 2004. Overview of radiologic efficacy of new treatments. Rheum. Dis. Clin. North Am. 30: 285-293.
7. QUINN, M.A. et al. 2005. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52: 27-35.
8. BRUCE, B. & J. F. FRIES. 2003. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J. Rheumatol. 30: 167-178.
9. WARE, J.E., JR. 2000. SF-36 health survey update. Spine. 25: 3130-3139.
10. MARSHALL, N.J. et al. 2004. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxf.) 43: 1034-1038.
11. KINGSLEY, G.H. et al. 2005. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. Rheumatology (Oxf.). 44: 629-632.
12. WOLFE, F. et al. 2005. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 52: 3873-3879.
13. GOEKOOP-RUITERMAN, Y.P. et al. 2005. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study): a randomized, controlled trial. Arthritis Rheum. 52: 3381-3390.
14. ASKLING, J. et al. 2005. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52: 1986-1992.
15. HOCHBERG, M.C. et al.. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin. Arthritis. Rheum. 34: 819-36.
16. WOLFE, F. & K. MICHAUD. 2004. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50: 1740-1751.
17. BONGARTZ, T. et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285.
18. PARKER, S.L. et al. 1997. Cancer statistics. CA Cancer J. Clin. 47: 5-27. Erratum, CA Cancer J. Clin. 47: 68.
19. ANDERSON, J.J. et al. 2000. Factors predicting response to treatment in rheumatoid arthritis. Arthritis Rheum. 43: 22-29.
20. ABBAS, ABUL K. & ANDREW H. LICHTMAN. 2004. Cellular and Molecular Immunology 5th ed., chapt. 11. Saunders/ Elsevier.
21. FRIES, J.F. et al. 1996. Reduction in long-termdisability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 39: 616-622.